Group items tagged

Pharmacy hub and spoke providers gathered at Westminster on Tuesday (November 19) to highlight to MPs the urgent need to implement Model One of Hub and Spoke legislation. This proposed model, aimed at making hub and spoke dispensing accessible to all pharmacies, was initially scheduled for rollout in January 2025, but has been delayed. Representatives from Centred Solutions, HubRx, and PillTime engaged with over 30 MPs at the event, which was organised with the support of former pharmacist and Labour MP Sadik Al-Hassan. They highlighted the significant benefits of hub and spoke for community pharmacies and stressed the need to extend its use across different legal entities. Sadik Al-Hassan, MP for North Somerset and officer for the Pharmacy APPG, expressed his support, saying, "Community pharmacies are a vital lifeline for our high streets and independents have always been at a disadvantage versus larger chains who can employ economies of scale. "Model One of the proposed legislation would allow the benefits of big pharmacies for smaller ones to help them focus on the service provision our NHS needs during this difficult financial time."

The UK government has announced plans to update legislation to enable more services and individuals to provide take-home supplies of naloxone - a life-saving opioid overdose antidote - over the next few weeks. Naloxone can immediately reverse the effects of an opioid overdose by reversing breathing difficulties. The medicine can be administered by anyone in an emergency. However, current legislation allows only drug and alcohol treatment services to supply it without a prescription to individuals for future use. The Department of Health and Social Care (DHSC) confirmed on Tuesday (14 May) that more professionals, including nurses, paramedics, police officers, probation officers and pharmacy professionals, will be able to supply the medicine without a prescription to save lives. Health and Social Care Secretary Victoria Atkins warned that opioid addiction can ruin lives and it accounts for the largest proportion of drug-related deaths across the UK.

Centred Solutions has been at the forefront of the pharmacy hub and spoke dispensing in England over the last few years. We have already demonstrated that hub and spoke dispensing is a realistic model of dispensing for pharmacy groups of all sizes. We've seen the massive difference that hub and spoke can make to community pharmacy. With pharmacies struggling to survive, the time has come to stop delaying and to now push ahead with model one of hub and spoke dispensing. In our experience, there is no risk with moving ahead with model one of hub and spoke legislation which would allow medicines to be returned from the hub to the pharmacy ready to be dispensed to the patient. We do however understand the need for more policy discussion around the second model of hub and spoke, where the hub sends the medication directly to the patient. This should not delay the implementation of model one. This model would immediately level the playing field for smaller and independent pharmacies, allowing them to use a hub and spoke model of their choice now to create capacity for clinical services. We feel strongly about this issue and that's why we are working alongside HubRx and PillTime to raise awareness.

New amendments to the Human Medicines Regulations will soon allow registered pharmacy technicians to supply and administer medicines under Patient Group Directions (PGDs). Laid before Parliament at the end of May, the legislative changes will come into effect from June 26, 2024, the Community Pharmacy England (CPE) announced today. The introduction of this new legislation follows an announcement made by the Department of Health and Social Care (DHSC) earlier this year. The regulatory adjustments provide the legal framework for pharmacy technicians to engage in the supply and administration of medicines under PGDs in the course of their professional practice. However, there will be no immediate change in the provision of community pharmacy services, the CPE noted

As the pharmacy profession continues to evolve, the role of Accredited Checking Technicians (ACTs) is becoming increasingly vital. Anne Ausden, the Deputy Manager of Jephsons Pharmacy, embodies this shift. With over 18 months in her current role, Anne oversees the pharmacy's daily operations, optimises medication use, and ensures high-quality patient care. Her work extends beyond the dispensary, offering blood tests, blood pressure monitoring, flu vaccines, and health education sessions. Anne, a 2023 Pharmacy Business Awards winner, shares her insights on the expanding role of ACTs with Pharmacy Business reporter Rudra Mulmule, particularly in light of recent legislative changes that allow pharmacy technicians to now administer medicines under a Patient Group Direction (PGD) and with the introduction of the Accuracy Checking Pharmacy Technician (ACPT) programme.

Community pharmacy is stuck in a vicious circle. Pharmacies are closing at an alarming rate whilst the government is talking about moving care away from hospitals and into the community to focus on preventative care. While the government talks about this vision for the future, the stark reality is that pharmacies are already struggling to meet the current Pharmacy First thresholds. And now we discover that one of the key components that could create capacity in pharmacy to deliver more clinical services has been put on hold…indefinitely. The recently published Darzi review, which was commissioned after the new government came to power to assess the state of the NHS, praised the value of community pharmacies and preventative services. But it recognised the level of pharmacy closures across the country and warned pharmacy access could be 'at risk'. Community pharmacy is ideally placed to deliver the government's vision of preventative care in the community. But let's all be clear, moving preventative services into community pharmacies has, so far, been nowhere near as successful as it could have been due to the current climate pharmacies find themselves in. The Pharmacy First scheme is a testament to this. Just this week it was announced that consultation thresholds for the Pharmacy First scheme have been reduced from 30 consultations to 20. It's the second time in three months that the thresholds have been reduced and it follows an intervention from Community Pharmacy England who wanted to "save many pharmacies from missing out on a vital payment this month." In June alone, 3,269 participating pharmacies failed to meet the threshold - that's almost a third of all community pharmacies in England.

The Association of the British Pharmaceutical Industry (ABPI) has laid out a series of urgent actions it wants the newly elected Labour government to implement within its first 100 days in office. Among the top priorities, the ABPI has emphasised the urgent need to appoint a new Chair and Chief Executive for the Medicines and Healthcare products Regulatory Agency (MHRA). Additionally, the ABPI has urged the new government to launch the Life Sciences Manufacturing Capital Grants Facility without delay. Other measures the ABPI wants Labour to prioritise include: Rapidly passing outstanding UK clinical trials legislation to enhance the UK's attractiveness for inward investment, including into research within the NHS. Increasing commercial flexibility in the NHS England Commercial Framework for New Medicines to remove barriers for companies to launch new medicines and indications so that NHS patients can access the latest innovative medicines.

The Royal Pharmaceutical Society (RPS) has taken a neutral stance on the Assisted Dying for Terminally Ill Adults (Scotland) Bill but underscores that pharmacists should have the right to refuse involvement in the process. The Bill, introduced to the Scottish Parliament by Liam McArthur MSP as a Private Members Bill, could make Scotland the first UK nation with assisted dying legislation if it passes into law. This week, the RPS in Scotland released its consultation response to the Scottish Parliament's Health, Social Care, and Sport Committee regarding the Bill, and made it clear that "the ability of pharmacists to conscientiously object to assisted dying is essential." The Society emphasised that "all pharmacists should have the right to take part, or not take part in the process, depending on their individual religious, moral or ethical beliefs." In its response, the RPS has also advocated for the inclusion of an opt-in section within the Bill.

The General Pharmaceutical Council (GPhC) has alerted pharmacists, pharmacy technicians, and pharmacy owners via email regarding new emergency legislation governing the prescribing and supply of puberty-suppressing hormones, commonly known as 'puberty blockers', for children and young people under 18 in England, Wales, and Scotland. The regulations apply to gonadotropin-releasing hormone (GnRH) analogues, used to suppress puberty as part of treating gender incongruence or gender dysphoria in individuals under 18. Effective from 3 June 2024, new private prescriptions for GnRH analogues from prescribers in the European Economic Area (EEA) or Switzerland who are not UK registered are banned from being dispensed in Great Britain for patients under 18. The emergency ban on these medicines will remain in effect until September 3, 2024, the Department of Health and Social Care (DHSC) announced on 29 May, stating that the action has been taken to address risks to "patient safety."

The Department of Health (DoH) in Northern Ireland has published a new Strategic Plan for Community Pharmacy, highlighting the vision and key priorities for the sector over the next 10 years. Co-developed by the DoH and Community Pharmacy Northern Ireland (CPNI), the representative body for community pharmacy owners, the plan aims to fully realise the potential of community pharmacy services to support better health outcomes from medicines and prevent illness. The vision outlined in the plan sees community pharmacies offering more clinical services, leveraging the skills of their teams to provide the public with safe, convenient, and faster access to care. According to DOH, the vision will be realised through four major reform programmes focusing on services, legislation, workforce, and digital enablers, alongside six strategic priorities. Together, these initiatives are anticipated to transform the role of community pharmacy within the Health and Social Care (HSC). Health Minister Robin Swann has extended his support to the new Community Pharmacy Strategic Plan, which builds on the previously agreed 3-year community pharmacy commissioning plan.

The Department of Health and Social Care (DHSC) has finally published its response to the 2022 consultation on hub and spoke dispensing. Considering the consultation evidence and further discussions, the government has expressed its intention to progress the proposals for enabling hub and spoke models across different legal entities as soon as possible. This will be achieved by using the enabling powers outlined in Part 2 of the Medicines and Medical Devices Act 2021 (MMDA) to amend the Medicines Act 1968 and the HMRs. Furthermore, the DHSC has decided to proceed with the implementation of the two models of hub and spoke dispensing that it consulted on. The government response to the consultation reads: "Having considered the responses, the government intend to proceed to implement the necessary changes to medicines legislation to remove the current restrictions that prevent the hub and spoke dispensing models from operating across different legal entities found in section 10 of the Medicines Act 1968.

Recent NHS data sheds light on the evolving landscape of fit note certification, indicating a gradual expansion of roles beyond traditional medical practitioners to pharmacists and nurses. This uptake in numbers coincides with the Department of Work and Pensions's (DWP) call for evidence in relation to fit note reform which will remain open till 8 July 2024. According to figures published by NHS Digital, during the nine-month period from April 2023 to December 2023, pharmacists certified a significant number of fit notes. Approximately 1.4 per cent of fit notes of the 8 million were issued by pharmacists while the rest were issued by the GP surgeries reflecting the impact following legislative amendments in July 2022, which extended certification authority to pharmacists, nurses, occupational therapists, and physiotherapists. In June 2022, the Pharmacists' Defence Association (PDA) advised pharmacists not to sign fit notes where the required therapeutic, diagnostic, or examination skills lie outside their scope of competence. The association remarked that healthcare professionals needed mandatory training under the Health Education England before they are fit to issue fitness notes to the public.

The Royal Pharmaceutical Society (RPS) in England and 19 other organisations have written to health secretary Wes Streeting, calling for a cohesive cross-government strategy to tackle medicine shortages across the UK. The letter stresses the need for actions to build supply chain resilience, support UK manufacturing, improve data connectivity, protect access to life-critical medicines, and reduce duplication across the NHS. As the government works on its 10-Year NHS Plan, the signatories emphasise the importance of ensuring patients' continued access to vital medicines, which are "an investment in their health." They underscore that the strategy would require engagement by the government across the NHS and the whole of the medicines supply chain, including manufacturers, suppliers, health professions, and patients. The letter also highlights that delays in accessing medicines could be reduced by changing legislation to empower community pharmacists to make minor amendments to prescriptions when shortages occur.

A new report from the Royal Pharmaceutical Society (RPS) has called on the government to create a national strategy to manage medicine shortages and to change legislation to empower community pharmacists to amend prescriptions when medicines are in short supply. Currently, patients are required to return to their GP to get their prescriptions amended, leading to delayed access to medication, increased bureaucracy, and additional strain on an already overburdened system. The RPS report, backed by charities and patient groups, proposes allowing pharmacists to make minor amendments, such as adjusting the quantity, strength, or form of prescribed medicines to ensure timely access for patients. Additionally, the report highlighted key factors causing medicine shortages, including manufacturing and supply chain issues, exacerbated by cost pressures and consolidation of manufacturing outlets. This along with unplanned spikes in demand, such as shifts in prescribing practice or increased diagnosis of some conditions, have created "a perfect storm of unstable supply"

In the pharmaceutical industry, maintaining high standards for water quality is crucial for ensuring product safety, efficacy, and compliance with regulatory standards. Water is a fundamental ingredient in drug manufacturing, and its quality directly impacts the production process and the end products. This makes adherence to water service compliance a legal obligation and a critical aspect of operational integrity. THE LEGAL COMPLICATIONS OF POOR WATER QUALITY Compliance with water quality standards in the pharmaceutical industry is mandated by regulatory agencies such as the MHRA, several regulations that set strict criteria for the types of water used, including purified water, water for injection, and sterile water. Failure to meet these standards can result in severe penalties, including product recalls, fines, and loss of manufacturing licenses. Regulatory compliance ensures the pharmaceutical companies adhere to legislations and avoid legal repercussions that can damage their reputation and financial standing

"Only around half of ICSs have a Chief Pharmacist," indicating a significant gap in leadership that hampers the pharmacy sector's ability to influence critical healthcare decision, a report on medicine optimisation by the Public Policy Projects (PPP) highlights. In PPP's latest report, a notable concern highlighted is the inadequate representation of pharmacy leadership within Integrated Care Systems (ICSs) despite the role of pharmacy being "central in the delivery of system priorities, with pivotal roles in improving population health and tackling inequalities". In recent years, the role of pharmacy within the NHS has evolved significantly with recent developments including Pharmacy First Services and legislative amendments that allows pharmacy technicians under PGDs to administer and supply medicines.

No Junk food ads on television will be allowed before the 9 pm watershed from October 2025 under a new law. The UK government confirmed the final details of advertising restrictions, including a ban on paid online junk food adverts, on Tuesday (3 December). The proposed legislation is part of a broader strategy to curb childhood obesity and address rising rates of obesity-related diseases such as diabetes and heart disease. Detailed guidance on which food and drink categories will be covered by the regulations has also been published. These measures are expected to remove 7.2 billion calories per year from UK children's diets, potentially preventing around 20,000 cases of childhood obesity. Health secretary Wes Streeting emphasised the need for such preventative action, stating: "Obesity robs our kids of the best possible start in life, sets them up for a lifetime of health problems, and costs the NHS billions. "This government is taking action now to end the targeting of junk food ads at kids, across both TV and online.

The Lords Food, Diet and Obesity Committee has expressed disappointment with the government's response to its recommendations for tackling the obesity crisis. In October 2024, the Committee released its report, Recipe for Health: A Plan to Fix Our Broken Food System, following a special inquiry. The report identified obesity and diet-related diseases as a public health emergency, costing society billions annually in healthcare expenses and lost productivity. It urged the government to develop a "comprehensive, integrated long-term new strategy to fix the food system", supported by a new legislative framework and outlined key actions that should be included. The government published its response to the report on 30 January 2025, but the Committee criticized it for lacking boldness and delaying many necessary measures. Baroness Walmsley, who chaired the Committee said: "In recent interviews with researchers, former prime ministers and health secretaries expressed regret that they had not done more to tackle obesity and advised the government to 'be bold and act fast'. "The report from the Lords Food, Diet and Obesity Committee recommended bold measures to be implemented immediately.

The Royal Pharmaceutical Society (RPS) has submitted evidence to the All-Party Parliamentary Group (APPG) on Pharmacy inquiry into medicines shortages in England. In its submission, the organisation has called on the government to develop a national strategy to address medicine shortages and change legislation to allow community pharmacists to amend prescriptions when medicines are in short supply. Tase Oputu, RPS England Board chair, welcomed the inquiry, and emphasised that medicines shortages continue to impact patients and the work of pharmacists daily. The RPS's evidence draws on its report, Medicines Shortages: Solutions for Shelves, which examines the issue in detail. The report revealed that pharmacy teams are spending more time chasing medicines supplies, identifying and switching patients to alternative medicines, taking their time away from other clinical activities.

The Royal Pharmaceutical Society (RPS) has expressed a neutral stance on assisted dying, while emphasising the importance of certain safeguards in any proposed legislation. In particular, they have urged the Bill Committee to include clauses addressing conscientious objection and criminal liability for health professionals involved. The Terminally Ill Adults (End of Life) Bill, which passed its second reading on 29 November 2024, would allow terminally ill adults to request assistance in ending their life, subject to safeguards and protections. The RPS has submitted a written response to a House of Commons committee examining the Bill, urging consideration of several key points. The RPS insisted that there should be "no obligation for any pharmacist to participate in any aspect of assisted dying if they feel this is against their personal beliefs." Instead, they proposed an "opt-in" model, allowing pharmacists and other healthcare professionals to choose to participate in aspects of assisted dying by completing the necessary training, rather than being required to "opt out." "This would help avoid the need for anyone ethically opposed to assisted dying to signpost to another health professional, as this can also pose an ethical dilemma." "This opt-in model would also help identify where it may be more difficult to access health professionals who are willing to support assisted dying, such as in a specific care setting or in remote regions," it explained.